Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers.

Laine J, Jokiranta TS, Eklund KK, Väkeväinen M, Puolakka K.

Biologics. 2016 Apr 1;10:67-73. doi: 10.2147/BTT.S96982. eCollection 2016.

2.

Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.

Simell B, Vuorela A, Ekström N, Palmu A, Reunanen A, Meri S, Käyhty H, Väkeväinen M.

Vaccine. 2011 Feb 24;29(10):1929-34. doi: 10.1016/j.vaccine.2010.12.121. Epub 2011 Jan 12.

PMID:
21236231
3.

Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae.

Melin M, Trzciński K, Antonio M, Meri S, Adegbola R, Kaijalainen T, Käyhty H, Väkeväinen M.

Infect Immun. 2010 Dec;78(12):5252-61. doi: 10.1128/IAI.00739-10. Epub 2010 Sep 20.

4.

The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement.

Melin M, Trzciński K, Meri S, Käyhty H, Väkeväinen M.

Infect Immun. 2010 Dec;78(12):5262-70. doi: 10.1128/IAI.00740-10. Epub 2010 Sep 20.

5.

Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination.

Väkeväinen M, Soininen A, Lucero M, Nohynek H, Auranen K, Mäkelä PH, Williams G, Käyhty H; ARIVAC Consortium.

J Pediatr. 2010 Nov;157(5):778-83.e1. doi: 10.1016/j.jpeds.2010.04.071. Epub 2010 Jun 14.

PMID:
20547399
6.

Interaction of pneumococcal histidine triad proteins with human complement.

Melin M, Di Paolo E, Tikkanen L, Jarva H, Neyt C, Käyhty H, Meri S, Poolman J, Väkeväinen M.

Infect Immun. 2010 May;78(5):2089-98. doi: 10.1128/IAI.00811-09. Epub 2010 Mar 1.

7.

Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B.

Melin M, Jarva H, Siira L, Meri S, Käyhty H, Väkeväinen M.

Infect Immun. 2009 Feb;77(2):676-84. doi: 10.1128/IAI.01186-08. Epub 2008 Dec 1.

8.

Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.

Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M.

Clin Vaccine Immunol. 2008 Sep;15(9):1391-7. doi: 10.1128/CVI.00110-08. Epub 2008 Jul 2.

9.

Efficacy of pneumococcal vaccination on chronic lymphocytic leukemia: should we rely on surrogate markers?

Sinisalo M, Vilpo J, Itälä M, Väkeväinen M, Taurio J, Aittoniemi J.

Vaccine. 2008 Jul 29;26(32):3959. doi: 10.1016/j.vaccine.2008.04.063. Epub 2008 May 16. No abstract available.

PMID:
18514977
10.

Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia.

Sinisalo M, Vilpo J, Itälä M, Väkeväinen M, Taurio J, Aittoniemi J.

Vaccine. 2007 Dec 21;26(1):82-7. Epub 2007 Nov 12.

PMID:
18053620
11.

Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.

Ekström N, Väkeväinen M, Verho J, Kilpi T, Käyhty H.

Infect Immun. 2007 Apr;75(4):1794-800. Epub 2007 Jan 29.

12.

Haemophilus ducreyi targets Src family protein tyrosine kinases to inhibit phagocytic signaling.

Mock JR, Vakevainen M, Deng K, Latimer JL, Young JA, van Oers NS, Greenberg S, Hansen EJ.

Infect Immun. 2005 Dec;73(12):7808-16.

13.

Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.

Ekström N, Ahman H, Verho J, Jokinen J, Väkeväinen M, Kilpi T, Käyhty H.

Infect Immun. 2005 Jan;73(1):369-77.

14.

Haemophilus ducreyi requires an intact flp gene cluster for virulence in humans.

Spinola SM, Fortney KR, Katz BP, Latimer JL, Mock JR, Vakevainen M, Hansen EJ.

Infect Immun. 2003 Dec;71(12):7178-82.

15.

Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae.

Romero-Steiner S, Frasch C, Concepcion N, Goldblatt D, Käyhty H, Väkeväinen M, Laferriere C, Wauters D, Nahm MH, Schinsky MF, Plikaytis BD, Carlone GM.

Clin Diagn Lab Immunol. 2003 Nov;10(6):1019-24.

16.

Inhibition of phagocytosis by Haemophilus ducreyi requires expression of the LspA1 and LspA2 proteins.

Vakevainen M, Greenberg S, Hansen EJ.

Infect Immun. 2003 Oct;71(10):5994-6003.

17.

Mutations in the lspA1 and lspA2 genes of Haemophilus ducreyi affect the virulence of this pathogen in an animal model system.

Ward CK, Latimer JL, Nika J, Vakevainen M, Mock JR, Deng K, Blick RJ, Hansen EJ.

Infect Immun. 2003 May;71(5):2478-86. Erratum in: Infect Immun. 2004 Feb;72(2):1221.

18.

Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.

Wuorimaa T, Dagan R, Väkeväinen M, Bailleux F, Haikala R, Yaich M, Eskola J, Käyhty H.

J Infect Dis. 2001 Nov 1;184(9):1211-5. Epub 2001 Sep 25.

PMID:
11598848
19.

Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants.

Väkeväinen M, Eklund C, Eskola J, Käyhty H.

J Infect Dis. 2001 Sep 15;184(6):789-93. Epub 2001 Aug 14.

PMID:
11517443
20.
21.

Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable?

Väkeväinen M, Jansen W, Saeland E, Jonsdottir I, Snippe H, Verheul A, Käyhty H.

Clin Diagn Lab Immunol. 2001 Mar;8(2):363-9.

Supplemental Content

Loading ...
Support Center